 KEEGO HARBOR, MI ACCESSWIRE January 11, 2021 ZIVO Bioscience, Inc. OTCQB:ZIVO a biotechagtech RD company engaged in the development and commercialization of therapeuticadditive product candidates originally derived from proprietary algal cultures, announces today that in its recent analysis of two poultry studies performed at separate research facilities, ZIVO product candidates provided statistically significant feed conversion benefits in healthy broiler flocks exposed to pathogens present in litter from previous flocks, emulating exposure that may occur in a typical broiler production environment. ZIVO has been developing a product candidate designed to boost immune response and combatting a broad range of infective pathogens, with the goal of improving feed conversion and productivity to provide cost-savings for poultry producers. 